Vmbook Online ordering

Derma Sciences Inc

Derma Sciences Inc. was a medical technology company focused on the development, manufacture, and marketing of novel wound care products. The company was previously listed on the OTCQX market under the stock symbol DSCI, but it was acquired by Integra LifeSciences Holdings Corporation in June 2017. Therefore, it is no longer possible to provide current information about Derma Sciences' financial performance or growth.

However, before the acquisition, Derma Sciences had reported financial results for the full year ended December 31, 2016. Here is some general information about the company's performance during that time:

* Total revenue: $37.2 million, a decrease of 5.9% from the previous year

* Gross profit: $22.3 million, or 60.1% of revenue

* Operating loss: $10.4 million

* Net loss: $9.5 million, or $0.50 per share

One of Derma Sciences' key products was its Advanced Wound Care (AWC) portfolio, which generated $31.1 million in revenue during the full year ended December 31, 2016. The company's growth strategy focused on expanding the adoption of its AWC products in the U.S. and international markets, particularly in China and Europe.

It is important to note that the information provided above is historical and may no longer be accurate or relevant. Following its acquisition by Integra LifeSciences Holdings Corporation, Derma Sciences' operations and financial performance have become part of Integra's consolidated financial statements, and the DSCI stock symbol is no longer in use.